Pharmacological interactions between serotonin and dopamine on behavior in the squirrel monkey

Psychopharmacology

Volumn 131, Issue 1, 1997, Pages 40-48

  Howell, Leonard L ^a,b   Czoty, Paul W ^a   Byrd, Larry D ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apomorphine; Dopamine; Drug self administration; Fixed interval schedule; GBR 12909; Operant behavior; Quinpirole; Second order schedule; Serotonin; Squirrel monkey

Indexed keywords

ALAPROCLATE; APOMORPHINE; COCAINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE UPTAKE INHIBITOR; FLUOXETINE; QUINPIROLE; QUIPAZINE; RECEPTOR SUBTYPE; RITANSERIN; SEROTONIN; SEROTONIN 2 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; VANOXERINE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONDITIONING; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG SELF ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SQUIRREL MONKEY;

ANIMALS; BEHAVIOR, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; SAIMIRI; SEROTONIN;

EID: 0031005372     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050263     Document Type: Article

References (51)

1. Anderson PH (1989) The dopamine uptake inhibitor GBR 12909: selectivity and molecular mechanism of action. Eur J Pharmacol 166: 493-504
2. Benloucif S, Keegan MJ, Galloway MP (1993) Serotonin-facilitated dopamine release in vivo: pharmacological characterization. J Pharmacol Exp Ther 265: 373-377
3. Bergman J, Madras BK, Johnson SE, Spealman RD (1989) Effects of cocaine and related drugs in non-human primates. III. Self-administration by squirrel monkeys. J Pharmacol Exp Ther 251: 150-155
4. 2 receptor agonists on schedule-controlled behavior of squirrel monkeys. J Pharmacol Exp Ther 273: 40-48
5. 3 receptors in rat striatum. J Pharmacol Exp Ther 251: 803-809
6. Byrd LD (1979) The behavioral effects of cocaine: rate dependency or rate constancy. Eur J Pharmacol 56: 355-362
7. Carroll ME, Lac ST, Asencio M, Kragh R (1990a) Fluoxetine reduces intravenous cocaine self-administration in rats. Pharmacol Biochem Behav 35: 237-245
8. Carroll ME, Lac ST, Asencio M, Kragh R (1990b) Intravenous cocaine self-administration in rats is reduced by dietary L-tryptophan. Psychopharmacology 100: 293-300
9. Cunningham KA, Callahan PM (1991) Monoamine reuptake inhibitors enhance the discriminative state induced by cocaine in the rat. Psychopharmacology 104: 177-180
10. De Simoni MG, Dal Toso G, Fodritto F, Sokola A, Algeri S (1987) Modulation of striatal dopamine metabolism by the activity of dorsal raphe serotonergic afferences. Brain Res 411: 81-88
11. Dray A, Gonye TJ, Oakley NR, Tanner T (1976) Evidence for the existence of a raphe projection to the substantia nigra in rat. Brain Res 113: 45-57
12. Dray A, Davies J, Oakley NR, Tongroach P, Vellucci S (1978) The dorsal and median raphe projections to the substantia nigra in the rat: electrophysiological, biochemical and behavioral observations. Brain Res 151: 431-442
13. Ennis C, Kemp JD, Cox B (1981) Characterization of inhibitory 5-hydroxytryptamine receptors that modulate dopamine release in the striatum. J Neurochem 36: 1515-1520
14. Fibiger HC, Miller JJ (1977) An anatomical and electrophysiological investigation of the serotonergic projection from the dorsal raphe nucleus to the substantia nigra in the rat. Neuroscience 2: 975-987
15. Goldberg SR (1973) Comparable behavior maintained under fixed-ratio and second-order schedules of food presentation, cocaine injection or d-amphetamine injection in the squirrel monkey. J Pharmacol Exp Ther 186: 18-30
16. Guan X-M, McBride WJ (1989) Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res Bull 23: 541-547
17. Heikkila RE, Manzio L (1984) Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake. Eur J Pharmacol 103: 241-248
18. Hervé D, Pickel VM, Joh TH, Beaudet A (1987) Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Res 435: 71-83
19. Howell LL, Byrd LD (1991) Characterization of the effects of cocaine and GBR 12909, a dopamine uptake inhibitor, on behavior in the squirrel monkey. J Pharmacol Exp Ther 258: 178-185
20. 2-selective dopamine antagonists in the squirrel monkey. J Pharmacol Exp Ther 262: 907-915
21. Howell LL, Byrd LD (1995) Serotonergic modulation of the behavioral effects of cocaine in the squirrel monkey. J Pharmacol Exp Ther 275: 1551-1559
22. Iyer RN, Bradberry CW (1996) Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J Pharmacol Exp Ther 277: 40-47
23. Kelland MD, Freeman AS, Chiodo LA (1990) Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther 253: 803-811
24. Kelleher RT, Goldberg SR (1979) Effects of naloxone on schedule-controlled behavior in monkeys. In: Usdin E, Bunney WE Jr, Kline NS (eds) Endorphins in mental health research. Oxford University Press, New York, pp 461-472
25. Lacosta S, Roberts DCS (1993) MDL 72222, ketanserin, and methysergide pretreatments fail to alter breaking points on a progressive ratio schedule reinforced by intravenous cocaine. Pharmacol Biochem Behav 44: 161-165
26. Lane JD, Pickering CL, Hooper ML, Fagan K, Tyers MB, Emmett-Oglesby MW (1992) Failure of odansetron to block the discriminative or reinforcing stimulus effects of cocaine in the rat. Drug Alcohol Depend 30: 151-162
27. Leccese AP, Lyness WH (1984) The effects of putative 5-hydroxytryptamine receptor active agents on d-amphetamine self-administration in controls and rats with 5,7-dihydroxytryptamine median forebrain bundle lesions. Brain Res 303 153-162
28. Loh EA, Roberts DCS (1990) Break-points on a progressive ratio schedule reinforced by intravenous cocaine increase following depletion of forebrain serotonin. Psychopharmacology 101: 262-266
29. Lyness WH, Moore KE (1983) Increased self-administration of d-amphetamine by rats pretreated with metergoline. Pharmacol Biochem Behav 18: 721-724
30. Morse WH, Kelleher RT (1966) Schedules using noxious stimuli. I. Multiple fixed-ratio and fixed-interval termination of schedule complexes. J Exp Anal Behav 9: 267-290
31. Nicolaou NM, Garcia-Munoz M, Arbuthnott GW, Eccleston D (1979) Interactions between serotonergic and dopaminergic systems in rat brain demonstrated by small unilateral lesions of the raphe nuclei. Eur J Pharmacol 57: 295-305
32. 3H] 5-hydroxytryptamine. Neuroscience 6: 115-138
33. 3 antagonists do not alter the discriminative stimulus properties of cocaine. Psychopharmacology 104: 475-478
34. Peltier RL, Emmett-Oglesby MW, Thomas WH, Schenk S (1994) Failure of ritanserin to block the discriminative or reinforcing stimulus effects of cocaine. Pharmacol Biochem Behav 48: 473-478
35. Peltier RL, Schenk S (1993) Effects of serotonergic manipulations on cocaine self-administration in rats. Psychopharmacology 110: 390-394
36. Phelix CF, Broderick PA (1995) Light microscopic immunocytochemical evidence of converging serotonin and dopamine terminals in ventrolateral nucleus accumbens. Brain Res Bull 37: 37-40
37. Porrino LJ, Ritz MC, Goodman NL, Sharpe LG, Kuhar MJ, Goldberg SR (1989) Differential effects of the pharmacological manipulation of serotonin systems on cocaine and amphetamine self-administration in rats. Life Sci 45: 1529-1535
38. Prisco S, Pagannone S, Esposito E (1994) Serotonin-dopamine interactions in the rat ventral tegmental area: an electrophysiological study in vivo. J Pharmacol Exp Ther 271: 83-90
39. 3 receptor antagonists attenuate cocaine-induced locomotion in mice. Eur J Pharmacol 186: 327-330
40. Richardson NR, Roberts DCS (1991) Fluoxetine pretreatment reduces breaking points on a progressive ratio schedule reinforced by intravenous cocaine self-administration in the rat. Life Sci 49: 833-840
41. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237: 1219-1223
42. Scheel-Krüger J, Braestrup C, Nielson M, Golembiowska K, Mogilnicka E (1977) Cocaine: discussion on the role of dopamine in the biochemical mechanism of action. In: Ellinwod EJ Jr, Kilbey MM (eds) Advances in behavioral biology, vol. 21, cocaine and other stimulants. Plenum Press, New York, pp 373-407
43. 2A/2C antagonist, reverses direct dopamine agonist-induced inhibition of mid-brain dopamine neurons. J Pharmacol Exp Ther 274: 735-740
44. 2 receptor antagonists reverse amphetamine-induced slowing of dopaminergic neurons by interfering with stimulated dopamine synthesis. J Pharmacol Exp Ther 260: 872-878
45. Spealman RD (1993) Modification of behavioral effects of cocaine by selective serotonin and dopamine uptake inhibitors in squirrel monkeys. Psychopharmacology 112: 93-99
46. 2 receptor antagonist, activates mid-brain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98: 45-50
47. Van Bockstaele EJ, Pickel VM (1993) Ultrastructure of serotonin-immunoreactive terminals in the core and shell of the rat nucleus accumbens: cellular substrates for interactions with catecholamine afferents. J Comp Neurol 334: 603-617
48. van der Zee P, Koger HS, Gootjes J, Hespe W (1980) Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake. Eur J Med Chem 15: 363-370
49. Wenger GR (1980) Cumulative dose-response curves in behavioral pharmacology. Pharmacol Biochem Behav 13: 647-651
50. Wise RA (1984) Neural mechanisms of the reinforcing actions of cocaine. In: Grabowski J (ed) Cocaine: pharmacology, effects and treatment of abuse. NIDA Research Monograph Series 50, US Government Printing Office, Washington, D.C., pp 84-1326
51. Woolverton WL, Kleven MS (1988) Multiple dopamine receptors and the behavioral effects of cocaine. In: Clouet D, Asghar K, Brown R (eds) Mechanisms of cocaine abuse and toxicity. NIDA Research Monograph Series 88, US Government Printing Office, Washington, D.C., pp 160-184